Analysts Maintain Optimism for Roivant Despite Insider Sales and Volatile Stock Performance Roivant Sciences’ stock has seen insider selling recently, including by Vivek Ramaswamy, but analysts remain bullish with several 'buy' ratings and price targets as high as $18. While the stock has experienced short-term volatility and a recent dip, long-term forecasts remain positive, supported by robust financials and pipeline progress.145